The client and the context

Mundipharma is a global network of independent associated companies with a presence in over 120 countries, employing more than 8,600 people and generating annual revenues in excess of $3.4 billion. Founded in 1952 and still privately owned, the network's purpose is to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers worldwide.

Over a two-year engagement, Umio completed three strategic programmes for Mundipharma — each applying our ecosystem strategy methodology to a distinct commercial and strategic challenge. Together they illustrate the breadth of what ecosystem-grounded analysis can do for a global pharma organisation operating across multiple therapeutic areas and market contexts.

Programme one - Betadine portfolio rationalisation

Mundipharma needed to make a critical commercial decision about its out-licensed antiseptic product portfolio - Betadine - across a complex range of therapeutic areas including wound and skin care, surgical, ocular, gynaecological, and oral applications.

Umio conducted a deep market and therapeutic area analysis across the full portfolio, evaluating every SKU against clinical efficacy, competitive profile, and growth potential. We identified the most commercially attractive assets within the portfolio and developed a detailed strategic and commercial justification for the board to rationalise, restructure, and reposition the portfolio for future growth.

The analysis gave Mundipharma the evidence base it needed to make a high-stakes portfolio decision with confidence - grounded in a comprehensive picture of current and future infection prevention and management practice, therapy area dynamics, and market conditions.

Programme two - NHS Payer Value Hotspots

In parallel, Umio led a year-long qualitative and economic review of NHS payer priorities - designed to identify the disease areas and clinical challenges where the burden was greatest, the unmet need was highest, and the potential for Mundipharma's capabilities to create genuine value was strongest.

This was not a standard market analysis. It began from an ecosystem perspective - mapping how the NHS was actually making value and investment decisions, what pressures were shaping commissioning priorities, and where the intersection between clinical need and payer willingness to invest was most commercially viable.

The review identified specific high-priority opportunity areas and target assets, and produced a value-based opportunity assessment framework that Mundipharma used to guide subsequent growth and investment decisions. The framework was designed to evolve with the landscape rather than provide a static picture - building a durable internal capability rather than a one-time insight.

Programme three - wound dressing in-licensing evaluation

The third programme addressed a specific in-licensing decision. A novel advanced wound dressing - with dominant market share outside Europe and strong internal advocacy within Mundipharma - was being considered for in-licensing into the European market. The dressing claimed to outperform rivals on multiple advanced wound management performance dimensions.

Umio was asked to determine whether the clinical utility and commercial potential justified the investment.

Our recommendation was that it did not.

Despite the dressing's strong performance profile and the internal enthusiasm behind it, a rigorous deep-dive into current clinical practice revealed that the evidence for a substantive unmet need and a viable European market was not strong enough to merit the investment required. The gaps between what the dressing offered and what European clinical practice actually needed - in the specific contexts, pathways, and competitive conditions that would determine adoption - were significant enough to make the commercial case fragile.

Recommending against investment when there is strong internal support for a technology is one of the harder things a strategy partner can do. It is also one of the most valuable. The willingness to surface an uncomfortable answer - backed by rigorous evidence rather than accommodating the client's preference - is what makes ecosystem-grounded strategy genuinely useful rather than merely confirmatory.

Mundipharma acted on the recommendation and ceased its interest in the asset.

What this demonstrates

The Mundipharma engagement illustrates a dimension of Umio's strategic capability that is distinct from its patient research and lived experience work - the application of ecosystem analysis to complex commercial and investment decisions in pharma and medtech.

The same capacity to see health systems in their full complexity - across clinical practice, market dynamics, payer behaviour, and lived experience - that produces better patient insight also produces better strategy. It starts from a more complete picture of reality than conventional market research or financial modelling, and it surfaces the dimensions of a decision that those methods leave invisible.